A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects

NCT ID: NCT03396250

Last Updated: 2019-03-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-02-12
• Study Completion Date: 2018-03-29

Brief Summary

To evaluate the relative bioavailability of Naproxen Sodium 220 mg and diphenhydramine hydrochloride (DPH HCL) 25 mg soft capsules (Test) versus Naproxen Sodium 220 mg and diphenhydramine hydrochloride 25 mg tablets (Reference) after a single oral administration under fasted condition in healthy adults subjects.

To assess the safety and tolerability of the investigational products in terms of advent events (AEs) and clinical parameters.

Conditions

Pain

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Test product + Reference product

Each treatment sequence consists of two treatment periods with each period consisting of 4 days starting with an overnight fast of at least 10 hours followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK (Pharmacokinetic) blood sampling period. The two drug administrations are separated by a 7 calendar days washout phase.

Group Type: EXPERIMENTAL

Naproxen sodium and diphenhydramine hydrochloride soft capsules

Intervention Type: DRUG

Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)

Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111)

Intervention Type: DRUG

Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)

Reference product + Test product

Each treatment sequence consists of two treatment periods with each period consisting of 4 days starting with an overnight fast of at least 10 hours followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK blood sampling period. The two drug administrations are separated by a 7 calendar days washout phase.

Group Type: EXPERIMENTAL

Naproxen sodium and diphenhydramine hydrochloride soft capsules

Intervention Type: DRUG

Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)

Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111)

Intervention Type: DRUG

Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)

Interventions

Naproxen sodium and diphenhydramine hydrochloride soft capsules

Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)

Intervention Type: DRUG

Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111)

Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy adult men or women
• Age 18 to 55 years inclusive;
• Body mass index 18.5 to 30.0 kg/m2 inclusive

Exclusion Criteria

• History of hypersensitivity symptoms with the use of naproxen/naproxen sodium, diphenhydramine hydrochloride/citrate, acetylsalicylic acid, other Nonsteroidal anti-inflammatory drugs (NSAIDs) or similar pharmacological agents or components of the products;
• Females who are pregnant or lactating;
• Vegetarian or restricted diet (e.g., gluten-free);
• Any active disease, acute or chronic;
• Have taken naproxen/naproxen sodium, DPH HCl or diphenhydramine citrate, DPH HCl or diphenhydramine citrate-containing products, acetylsalicylic acid (ASA), ASA-containing products, acetaminophen, ibuprofen, any other NSAID (Over-the -counter [OTC] or prescription) or NSAID containing products, xanthines, antihistamines or caffeine-containing products (e.g. coffee, tea and chocolate) 7 days prior to dosing or during the Dosing Periods, other than trial treatment;
• Use of any over-the-counter or prescription medications, vitamins or herbal supplements (except acceptable forms of birth control) within 7 days prior to dosing or throughout the trial, unless in the opinion of the Investigator, the medication will not interfere with the trial procedures, data integrity, or compromise the safety of the subject;
• Positive test for Human immunodeficiency virus (HIV) antibodies and antigens;
• Positive test for hepatitis B surface antigen (HBsAg) test;
• Positive test for anti-hepatitis C virus (Anti-HCV) antibodies;
• In the judgment of the investigator, any need of other medication during the trial besides the test and reference study medication;
• Recently had (past 30 days) or plan to have surgery, an invasive procedure, tattoos or piercings during the trial or within 2 weeks after treatment;
• More than moderate alcohol consumption (>40 g of alcohol regularly per day);
• Positive alcohol or drug screen at Screening or on Day -1 of each dosing period.
• Any history or suspicion of barbiturate, amphetamine, benzodiazepine, cocaine, opiates, methamphetamine or cannabis abuse;
• Loss of blood in excess of 50 mL to 499 mL within 30 days or 500 ml within 56 days of the first dose of trial treatment (e.g., donation, plasmapheresis or injury);
• Excessive sports or sauna within 5 days before start of the treatment phase and unwilling to abstain during the trial;
• Have a platelet count <150,000/mm3 and in the judgment of the investigator, presents a significant bleeding risk;
• History of gastrointestinal bleeding or perforation, related to previous NSAID therapy. Active, or history of recurrent peptic ulcer/hemorrhage (two or more distinct episodes of proven ulceration or bleeding);
• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases (including glaucoma or benign prostatic hypertrophy) or malignancies or any other disease or condition which could influence the metabolism of the drug;

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Bayer

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Bayer Study Director

Role: STUDY_DIRECTOR

Bayer

Locations

ICON Development Solutions, LLC

San Antonio, Texas, United States

Countries

United States

Related Links

https://clinicaltrials.bayer.com/

Click here to find results for studies related to Bayer products.

Other Identifiers

17934

Identifier Type: -

Identifier Source: org_study_id